Skip to main content
Premium Trial:

Request an Annual Quote

Howard Robin, Barry Greene, Philip Padou

Premium
Nektar Therapeutics said this week that it has named Howard Robin as its new president and CEO, effective Jan. 15.
 
Robin currently serves as president and CEO of Sirna Therapeutics, which was acquired by Merck for $1.1 billion in cash (see RNAi News, 1/4/2007).
 
Prior to heading up Sirna, Robin was corporate vice president and general manager of Berlex Laboratories’ US therapeutics division.
 

 
Acorda Therapeutics said this week that it has appointed Barry Greene to its board of directors.
 
Greene is currently the COO of Alnylam Pharmaceuticals.
 

 
Bio-Rad said last week that Philip Padou, one of the company’s directors, has died at the age of 72.
 
Padou had sat on Bio-Rad’s board since 1980. The company said it plans to seek a replacement.

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.